| 摘要 |
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.; |
| 主权项 |
1. A compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein: R1 is chosen from —C(O)NH(OH) and —N(OH)C(O)R9; R2 is chosen from aryl, heteroaryl, and heterocycloalkyl, each of which is optionally substituted with 1 to 3 substituents independently chosen from halo, alkyl, cycloalkyl, haloalkyl, hydroxyl, alkoxy, and nitrile; A is chosen from aryl and heteroaryl; R3 and R4 are independently chosen from hydrogen, alkyl, halo, NHSO2R10, C(O)NR11R12, NR11R12, nitrile, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl, each of which is optionally substituted with 1 to 3 substituents independently chosen from halo, alkyl, cycloalkyl, haloalkyl, hydroxyl, alkoxy, aryl, heteroaryl, and nitrile, wherein alkyl and alkoxy are optionally substituted with amino, (alkyl)amino or di(alkyl)amino; for each occurrence, R5, R6, R7, and R8 are independently chosen from hydrogen and lower alkyl; R9 is chosen from hydrogen and lower alkyl; R10 is chosen from lower alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; R11 and R12 are independently chosen from hydrogen, lower alkyl, alkoxy, lower haloalkyl and cycloalkyl wherein alkyl and alkoxy are optionally substituted with amino, (alkyl)amino or di(alkyl)amino, and m and m′ are independently chosen from 0, 1, 2, 3 and 4, provided that 2≦(m+m′)≦4. |
